How Bone Ages at Every Scale — And How to Reverse It

As the global population ages, bone degenerative diseases — osteoporosis, fragility fractures, and related conditions — are becoming one of medicine's most pressing challenges. Yet the field has long focused on a single metric, bone mineral density, while the true biology of bone aging operates across at least four interacting levels simultaneously. This comprehensive review from the Department of Orthopedics at Peking University Third Hospital provides the most systematic synthesis to date of that multi-scale complexity.

At the macroscopic level, aging bone loses mass, deteriorates microarchitecturally, and weakens biomechanically — the visible end result of decades of molecular wear. At the molecular level, the review documents how genetic mutations accumulate, epigenetic marks shift, oxidative stress mounts, the senescence-associated secretory phenotype (SASP) inflames surrounding tissue, and key pathways such as Wnt and RANK-L fall out of balance. At the cellular level, telomere attrition, mitochondrial dysfunction, endoplasmic reticulum stress, impaired protein quality control, and altered nutrient sensing all converge on cellular senescence — a state in which cells stop dividing but actively damage neighbors. Systemically, chronic low-grade inflammation, declining sex hormones, and extracellular matrix remodeling complete the picture.

The intervention section is equally thorough. Non-pharmacological strategies — weight-bearing exercise, protein-adequate diets, smoking cessation, and alcohol reduction — address multiple mechanisms simultaneously and carry no serious side effects. Approved pharmacological options include antiresorptive agents (bisphosphonates, denosumab) and anabolic drugs (teriparatide, romosozumab). Senolytics such as dasatinib plus quercetin, which selectively eliminate senescent bone cells, represent the most mechanistically targeted approach and are generating significant clinical trial activity.

Emerging frontiers include bone organoids for drug testing, gene therapies targeting aging pathways, and tissue engineering scaffolds capable of restoring both structure and function. The authors argue that future progress requires integrating multi-omics data into a unified bone aging atlas and building multimodal risk assessment tools.

Limitations include that this is a narrative review rather than a meta-analysis, meaning evidence quality across cited interventions varies substantially. The summary here is also based solely on the abstract.